Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safety Of Enicepatide In Participants With Overweight Or Obesity And Heart Failure With Reduced Ejection Fraction'. The following are the other relevant details related to the trial:
Therapeutic Area: Cardiology
Trial Centre(s):
Changi General Hospital
National Heart Centre
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Huang Weiliang
Dr David Sim
Dr Sia Ching Hui
Published by HT Digital Content Services with permission from Health Daily Digest....